A Study of LY2216684 in Participants With Major Depression Disorder

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin Reuptake Inhibitors (SSRI) for up to approximately 1 year in participants with Major Depressive Disorder (MDD) who were partial responders to their SSRI treatment.

Timeline

Start

2011-08

Primary completion

2014-01

Completion

2014-01

Drugs

Indications